Hospital performs first iPS heart cell surgery
A hospital in Japan performed the first clinical transplantation of commercially produced sheets of heart muscle cells derived from induced pluripotent stem (iPS) cells into a woman in her 50s, following the therapy's conditional government approval in March. The hourlong operation, led by surgeon Yoshiki Sawa who developed the technique with Nobel laureate Shinya Yamanaka, follows earlier trials where eight ischemic heart disease patients had eased symptoms and four showed improved heart function. The team plans 75 similar operations by 2033 and aims for full authorization after seven years of safety and efficacy data.
First clinical iPS heart cell transplant performed under conditional approval.
Context
Japan granted conditional approval for the iPS heart therapy in March. Trials on eight…
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorRegulatory willingness to conditionally…Locked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsAnnual count of iPS heart-sheet…Locked
- Probability of ChangeLocked
- Debate PointsLong-term safety and efficacy remain…Locked
- Historical ParallelJapan's earlier conditional approval of…Locked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsWill the 75 planned operations complete…Locked
- Pros & ConsClinicians: therapy may improve heart…Locked
Free account — 3 full analyses a day, no card.